|

S-1 Clinical Trials

15 actively recruiting trials

Also known as: Tegafur Gimeracil Oteracil Potassium Capsule, Tegafur,Gimeracil and Oteracil Potassium Capsules, Tegafur-gimeracil-oteracil potassium

Pipeline

Phase 2: 11Phase 3: 1Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • Sun Yat-sen University3
  • The First Affiliated Hospital with Nanjing Medical University2
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • Ruijin Hospital1
  • Qilu Hospital of Shandong University1

Indications

  • Cancer15
  • Gastric Cancer6
  • Recurrent or Metastatic Nasopharyngeal Carcinoma2
  • Linitis Plastica of Stomach1
  • Immunotherapy Gastrict Cancer1

Other15 trials

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Phase 1/2
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
Phase 2
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Phase 3
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Phase 2
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Phase 2
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
Phase 2
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Phase 2
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/2
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Phase 2
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Phase 2
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Phase 2/3
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.